Rep. Kevin Hern Sells Off Shares of Organon & Co. (NYSE:OGN)

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Organon & Co. (NYSE:OGN). In a filing disclosed on August 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Organon & Co. stock on August 5th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Diageo (NYSE:DEO) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Estee Lauder Companies (NYSE:EL) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Versant (NASDAQ:VSNT) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Comcast (NASDAQ:CMCSA) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Kenvue (NYSE:KVUE) on 8/5/2026.

Organon & Co. Trading Up 0.3%

Shares of OGN opened at $13.65 on Wednesday. Organon & Co. has a one year low of $5.69 and a one year high of $13.66. The stock has a 50-day moving average price of $13.50 and a 200 day moving average price of $10.65. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95. The company has a market capitalization of $3.59 billion, a P/E ratio of 17.73, a P/E/G ratio of 1.26 and a beta of 1.55.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $0.02 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.’s dividend payout ratio is currently 10.39%.

Analyst Ratings Changes

Several equities analysts have recently commented on OGN shares. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and increased their target price for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. BNP Paribas Exane restated a “neutral” rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Finally, Weiss Ratings lowered shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Organon & Co. presently has a consensus rating of “Reduce” and an average price target of $11.40.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of OGN. Farther Finance Advisors LLC increased its holdings in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after acquiring an additional 2,033 shares during the last quarter. Allied Private Wealth LLC bought a new position in Organon & Co. during the second quarter worth $33,000. Eurizon Capital SGR S.p.A. bought a new position in Organon & Co. during the fourth quarter worth $44,000. Kestra Advisory Services LLC acquired a new position in Organon & Co. in the fourth quarter worth $47,000. Finally, WNY Asset Management LLC acquired a new position in Organon & Co. in the first quarter worth $64,000. Institutional investors own 77.43% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.